Targeted therapy options on the rise

The pathophysiology of prurigo nodularis (PN) is multifactorial and complex, but great progress has recently been made in terms of treatment options. In addition to the monoclonal antibodies dupilumab and nemolizumab approved on the basis of the PRIME/PRIME2 studies and the OLYMPIA study program, various systemic agents are currently being investigated in phase II and III clinical trials, including several monoclonal antibodies and Janus kinase inhibitors.